Program

Check back for updates on the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium program.

Designed for clinicians, scientists, and all other members of the cancer care and research community, this three-day meeting focuses on the clinical application of scientific advances in immuno-oncology. At the 2019 Symposium, expert faculty will offer new insights on the application of immunotherapy in lung cancer, genitourinary cancers, melanoma and other skin cancers, breast cancer, and gynecologic cancers. Faculty will also discuss the clinical relevance of immunogenomics, T Cell therapies, cancer vaccines, the microbiome, and promising combination strategies.

Each day of the 2019 program will feature a Keynote Lecture given by world-renowned experts on exciting topics in immuno-oncology including the future of the field and T Cell differentiation and exhaustion.

For members of the cancer care team looking for a foundational understanding of immunology, the Symposium will also feature an early morning “Immunology 201” session.

The meeting will also offer several opportunities for robust networking, discussion, and engagement with faculty members and other attendees. Participants in Networking Roundtable sessions will interact with leaders in the field to discuss research and treatment in all of the disease-sites covered by the educational program. During the Trainee and Early-Career Networking Luncheon, faculty will lead small-group discussions on the clinical application of immuno-oncology specifically tailored for early-career attendees.

7:00 AM-7:55 AM

Complimentary Continental Breakfast

7:55 AM-9:00 AM Welcome and General Session 7: Immunotherapy in Breast and Gynecologic Cancers—Building on Recent Successes

Kunle Odunsi, MD—Chair
Roswell Park Comprehensive Cancer Center

Brian J. Czerniecki, MD, PhD—Chair
H. Lee Moffitt Cancer Center & Research Institute

Elizabeth A. Mittendorf, MD, PhD
Dana-Farber/Brigham and Women’s Cancer Center
Welcome and Breast Cancer Immunotherapy: Building on Recent Successes

Daniel Powell, PhD
University of Pennsylvania
T-Cell Therapy for Gynecologic Malignancies

Panagiotis A. Konstantinopoulos, MD, PhD
Dana-Farber Cancer Institute
Immunotherapy in BRCA Mutation Carriers

Panel Question and Answer
9:05 AM-9:45 AM Keynote Lecture

Rafi Ahmed, PhD
Emory University
T-Cell Differentiation and Exhaustion

Panel Question and Answer
9:45 AM-10:15 AM Break
10:15 AM-11:30 AM

Oral Abstract Session C

 

Brian J. Czerniecki, MD, PhD—Chair
H. Lee Moffitt Cancer Center & Research Institute

 

Madhav V. Dhodapkar, MBBS—Chair
Emory University

 

Abstract 1: Final analysis of Nelipepimut-S plus GM-CSF with trastuzumab versus trastuzumab alone to prevent recurrences in high-risk, HER2 low-expressing breast cancer: A prospective, randomized, blinded, multicenter phase IIb trial.
First Author: Annelies Hickerson, MD

 

Abstract 2: Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer.
First Author: Premal Thaker, MD

 

Kunle Odunsi, MD
Roswell Park Comprehensive Cancer Center
Discussion

 

Abstract 74: Enhanced antitumor effect and lower viral reactivation with high doses of ex vivo expanded NK cells administered after haploidentical transplantation.
First Author: Stefan Ciurea, MD

 

Jeffrey Miller, MD
University of Minnesota
Discussion

 

Panel Question and Answer

11:30 AM-1:00 PM

Complimentary Boxed Lunch

1:00 PM-2:00 PM General Session 8: Targeting the Microbiome in Cancer Therapy
 

Jennifer A. Wargo, MD, MMedSc—Chair
The University of Texas MD Anderson Cancer Center


Ami S. Bhatt, MD, PhD—Chair
Stanford University
 

Jennifer A. Wargo, MD, MMedSc
The University of Texas MD Anderson Cancer Center
Modulating the Gut Microbiome to Enhance Responses to Immunotherapy


Ami S. Bhatt, MD, PhD
Stanford University
Targeting Gut Microbiota in Hematologic Malignancies

 

Tessa Andermann, MD
Stanford University
Microbiome Manipulation in Cancer: Still at the Bench, or Ready for the Bedside?

Panel Question and Answer

2:00 PM-2:30 PM Break
2:30 PM-4:00 PM General Session 9: Promising Combination Strategies

Kim A. Margolin, MD, FASCO—Chair
City of Hope

Michael Morse, MD—Chair
Duke University Medical Center

Ryan J. Sullivan, MD
Massachusetts General Hospital
Current and Promising Combination Immunotherapy for Cancer

Yousef Zakharia, MD
University of Iowa Holden Comprehensive Cancer Center
Combinations of Locoregional Therapies and Systemic Therapy
 

Jeffrey Miller, MD
University of Minnesota
Enhancing Natural Killer Cells with Specificity to Treat Cancer

 

Abstract 12: A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): Interim safety, efficacy, and pharmacokinetic findings in advanced cancers.
First Author: James Harding, MD


Michael Morse, MD
Duke University Medical Center
Discussion

Panel Question and Answer